The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma (ICPT - Get Report) offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013.
Here are the charts:
^NBI data by YCharts
And here's what the NBI looked like for the first 9 days of 2013:
^NBI data by YCharts
One big difference between 2013 and 2014 to note: The J.P. Morgan Healthcare Conference ran early last year -- Jan. 7-10, 2013, so investors were already reacting to what was an incredibly upbeat outlook offered by biotech companies.
This year's J.P. Morgan confab starts on Monday and runs through Thursday, so we'll check back on these charts late next week to see if 2014 catches up to 2013's performance.
Intercept is obviously the best-performing drug stock in this very young 2014, but other stocks strong out of the gate include Neurocrine Bioscience (NBIX - Get Report), Epizyme (EPZM), Zalicus ZLCS, Oramed Pharma (ORMP) and Atherthys (ATHX - Get Report). In other words, the speculative fervor we saw last year has not abated.
10/14/15 - 11:47 AM EDT
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
11/25/15 - 13:09 PM EST
11/25/15 - 12:59 PM EST
11/24/15 - 08:30 AM EST
11/23/15 - 08:30 AM EST
11/23/15 - 01:00 AM EST
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.